Canaccord Genuity Remains Bullish on Heartware (HTWR) Following Agreement to Acquire Valtech Cardio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pre-Open Stock Movers 09/02: (SURG) (VRA) (WMGI) Higher; (RJET) (DGLY) (HTWR) Lower (more...)
September 2, 2015 9:23 AM EDTA listing of stocks moving in the pre market trading session:
Synergetics USA, Inc. (NASDAQ: SURG) 53% HIGHER; Synergetics USA and Valeant Pharmaceuticals International ("Valeant"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), announced that they have entered into a definitive agreement under which Valeant will acquire Synergetics for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional cash payments... More
Heartware International's (HTWR) Valtech Cardio Acquisition Doesn't Make Sense, Says Northland
September 2, 2015 9:18 AM EDTNorthland Capital Markets maintained an Underperform rating on Heartware International (NASDAQ: HTWR) with a price target of $60. Analyst Suraj Kalia said the company's acquisition of Valtech Cardio does not makes sense.
Kalia explained, "Valtech is a pre-revenue company developing surgical & transcatheter mitral repair / replacement... More
Raymond James Downgrades Heartware (HTWR) to Market Perform
September 2, 2015 8:36 AM EDTRaymond James downgraded Heartware Int'l (NASDAQ: HTWR) from Outperform to Market Perform and removed its price target (prior $102.00).
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $81.81 yesterday.
... MoreBTIG Downgrades Heartware Int'l (HTWR) to Neutral
September 2, 2015 8:13 AM EDTBTIG downgraded Heartware Int'l (NASDAQ: HTWR) from Buy to Neutral. The change follows its acquisition of Valtech.
"While we understand the rationale of this acquisition and it may prove to be a strong asset over the next 3-5 years, we anticipate there... More
Heartware (HTWR) to Acquire Valtech Cardio
September 1, 2015 4:25 PM EDTHeartware (NASDAQ: HTWR) announced today that it has entered into a definitive agreement to acquire Valtech Cardio, Ltd. ("Valtech"). Valtech is a privately held company that specializes in the development of innovative surgical and transcatheter valve repair and replacement devices for the treatment of the most prevalent heart valve diseases mitral valve regurgitation (MR) and... More
